<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044443</url>
  </required_header>
  <id_info>
    <org_study_id>CRD1012</org_study_id>
    <nct_id>NCT04044443</nct_id>
  </id_info>
  <brief_title>IMPEDE and IMPEDE-FX Embolization Plug Registry</brief_title>
  <acronym>EMBO-PMS</acronym>
  <official_title>Post Market Registry of the IMPEDE and IMPEDE-FX Embolization Plugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shape Memory Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shape Memory Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      EMBO-PMS is a prospective, multicentre, registry study of the IMPEDE and IMPEDE-FX
      Embolization Plug Systems
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Safety - Rate of freedom from serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Rate of technical success (embolization of target vessel)</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Technical success, defined as embolization of the target area after deployment of the study device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Rate of recurrence of clinical symptoms, based on original complaint</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants free of recurrent clinical symptoms, based on clinical symptoms of original complaint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Rate of treated vessel occlusion</measure>
    <time_frame>90 days</time_frame>
    <description>Treated vessel occlusion, measured per study site standard of care for the original condition treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Rate of freedom from serious adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Vascular Embolization</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IMPEDE or IMPEDE-FX</intervention_name>
    <description>Peripheral vascular embolization</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult study participants considered candidates for a peripheral vascular embolization
        procedure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study participant is â‰¥18 years of age

          -  Study participant is considered a candidate for arterial or venous embolization of the
             peripheral vasculature

        Exclusion Criteria:

          -  Study participant has an inability to provide written informed consent

          -  Study participant/treatment outside of the approved study device labeling,
             instructions for use (IFU)

          -  Study participant is a prisoner or member of other vulnerable population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Lobotesis, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Charing Cross Hospital (Imperial College Healthcare NHS Trust)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St George's Hospital (St George's University Hospitals NHS Foundation Trust)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ingham</last_name>
      <phone>+44 (0)20 8725 2876</phone>
      <email>Robert.Ingham@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Morgan, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Loftus, MBChB MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leto Mailli, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raj Das, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital (Imperial College Healthcare NHS Trust)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chido Chiwome</last_name>
      <phone>+44 (0)20 3313 0764</phone>
      <email>imperial.radresearch@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Mohamad Hamady, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

